Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been established for IMP761, its proprietary preclinical candidate for autoimmune diseases.   The 200L scale attained by Northway Biotech, an end-to-end biopharmaceutical contract development and manufacturing organization (CDMO), will ensure supply of IMP761 for IND-enabling studies and ensuing clinical...